BioMarin signs global patent license deal with Ascendis for TransCon CNP products
Bitget2026/09/30 20:16- BioMarin signed a settlement and license agreement with Ascendis covering TransCon CNP products, effective Aug. 28, 2026.
- Ascendis received a non-exclusive, worldwide, transferable license to BioMarin patents for development and commercialization across current and future indications.
- BioMarin will collect royalties of 20% on U.S. net sales, 18% in the EU, Brazil, South Korea through May 2030.
- Pending patent litigation between the companies will be dismissed with prejudice under the agreement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CryptoQuant analyst says the altcoin market cap has shrunk by about $20 billion
![Fu Peng: Pay attention to the potential shift in copper from stockpiling to bottleneck logic [Fu Peng Commentary]](https://img.bgstatic.com/external-content/5bba8cd4c8254af78616bb3a2e614b63.jpg?w=420&h=236&f=webp)
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
Crypto prices
More
